Member Info for SiriusB

No

So what are we expecting the news flow to be here:

Avacta investor presentation tomorrow at 5pm. Hoping for some good insights on new product opportunities here.

Danaher earnings call on Thursday at 1pm BST. Not expecting anything in that to be honest.

I still think we are due news here from the Cytiva partnership as the timescales indicated a product to be ready this week. Will this come before the presentation tomorrow? Let’s see...

Well done bench and all who are in here. I’d personally take your friends money out (their decision). It could go to £5 or it could go sideways, down who knows. It’s a nice profit. Need to temper their expectations of investing though. Especially in AIM. Companies like this are very rare.

Anyone on here sitting on a 6 or 7 figure profit yet? Must be a few but god knows how you hold. That £5k buy at 16p still hurts but I am certain I never would have help past £1

£500m MCAP wouldn’t be outrageous so 250p is my first target but if we end up with several deals and products that works then I can’t even imagine where we could end up

Agreed seethreeIPO. Posts like even this one just clog up the board when there is so much goodness to talk about with Avacta.

Out of interest which of the two current AIM boards where you on?

On latest deal from interview:

2 weeks to finish developing the test and 2 weeks to complete trials for approval.

We now have two exciting deals on the table being worked in parallel with more to come. The updates here are going to be very frequent as milestones, approvals and orders come rolling in each week. I just hope we get to see the company grow before a buyout happens

Timster, there is unlikely to be a retrace on Monday given anticipation of the presentation on Wednesday. Just bought more. It will probably retrace now...

I’m sure we’ve all made poor investments. No need to single people out. Did you get burnt in SXX?

How is their investment in another company relevant to AVCT?

What a gift the drop was this am to load up. Bought into so quickly I missed it but will take a few more at this level.

Has anyone tried to crunch the numbers based on what 12.5 metric tonnes of ferric maltol would translate to in finished product, using best guess assumptions, and hence planned sales in 2021? I feel this calc should be possible with some degree of accuracy so will do some research over the weekend.

It seems like the US deal is on track for this quarter to me but the only bit I don’t like is the June IP hearing. I don’t know if it is effecting the US negotiations, it didn’t the Chinese deal, so would be good to get clear of it.

If everyone could stop buying please and let the price hang around 90p or better still sell now so it can go lower. Most of my shares in US market so need to wait until 2.30pm for a top up here. News next week is going to be big although I’m surprised we haven’t seen an RNS regarding affimers being sent to Cytiva for the next stage in development. Perhaps they will just say next week the product is ready for testing...

Just looking through the holdings RNSs and the corporate presentation. With the recent holdings does that mean that UFG now hold c. 60% of the company and IIs together hold 90%? I thought some may be transfers but we should have seen the corresponding reduction in holdings. This share wasn’t very liquid before but if everyone holds tight that may prevent some movement in the sp. Not that I’m complaining as we just took off from 70s to 90p :-)

Nothing to do with MMs other than the fact they create the market based on buys vs sells. The share price is going down as people want to sell their shares. The fact there is not many in circulation means the volatility can be magnified. Good luck trying to buy any shares on the dips

Ade, I got a quote for £5k at 16p and didn’t take it so feel your pain. Been averaging up since 71p now the risk is reducing

I think a lot in here moved over from NCYT and have first hand experience in trying to trade the spikes and retraces. It didn’t work at all and holding was the best strategy there. In fact the lack of retraces since the last news makes me think most know this now. Worth noting that NCYT rose most on days when there was no news so don’t get over excited when it drops. Just hold until a more suitable valuation for this company has been achieved

Solid upside...at least 100% from here just on news of successful trials at Cytiva, CE Mark, approvals

130p to sell 10k shares. This is motoring this am!!!

RK be sure to tell us when you selling into the rise this time as well please

I don’t think the US open has anything to do with it. This is UK listed. They can buy when the market is open in the UK. I think it’s more down to seasoned investors buying into the close

Hi all, I got in relatively late to the party here. Was watching from last year when investors were predicting a recession at some point and forecasting gold to rise to $1800/oz. They were right. I do feel that now $3000 has been mentioned we will got it in the next 12-24 months. I bought my latest tranche last week at 8p. I will be slicing a big chunk out at 10-12p as I’m risk averse these days. Reading the comments on here it sounds equally weighted between holders and people planning to sell some. Can’t really be certain of people’s intentions on a BB but I must say this is one of the best boards on LSE. I’m interested to know for those that are going to sell some, where the the money go next. A few have said to pay off mortgage etc but if reinvesting what could possibly be more tempting out there than GGP?

Tech, Ferrari, comparing the companies like that is completely wrong. NCYT 2019 revenue is irrelevant to the current orders/sales they have received. AVCT was a greater market cap to start with before they announced their testing development/partnership. They have some other great stuff in their business. What we can do is compare the sales success NCYT has achieved if we can get a test to market quickly and the demand is still there (which it will be). £250m MCAP isn’t outrageous if we have the same success as NCYT